CHANEX

Welcome to the Brand page for “CHANEX”, which is offered here for Clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing liposome reagents suitable for gene therapy; therapuetic compositions containing nucleic acids for gene therapy; pharmaceutical preparations containing nucleic acid for use in the treatment of cancer, hiv and aids-related infections and bodily conditions associated with impaired immunosystems, viral and bactierial diseases, cancer and cystic fibrosis; pharmaceutical preparations in the field of gene therapy; pharmacuetical preparations for the treatment of cystic fibrosis;instruments and apparatus for the administration of gene therapy, syringes, scalpels, catheters, tubes for the administration of gene therapy products; surgical and medical apparatus and instruments, syringes, scalpels, catheters and tubes for medical services;genetic engineering services and biotechnology services, development and commercialization of therapeutic vaccines and gene-based therapies in respect of oncology and neurotherapy;.

Its status is currently believed to be active. Its class is unavailable. “CHANEX” is believed to be currently owned by “Oxford BioMedica plc”.